Navigation Links
WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2009 Results
Date:3/8/2010

66,035,918 73,654,710 63,775,220 * >100% or not meaningful Note 2: Financial results of AppTec were consolidated as of January 31, 2008. WUXI PHARMATECH (CAYMAN) INC. RECONCILIATION OF GAAP TO NON-GAAP (in thousands of U.S. dollars, except ADS data and per ADS data) Three Months Ended Twelve Months Ended December 31, December 31, 2009 2008 % 2009 2008 % GAAP gross profit -continuing operations 29,236 20,274 44% 108,405 96,342 13% GAAP gross margin -continuing operations 40% 31% 40% 38% Adjustments: Share-based compensation 842 1,004 2,685 3,020 Amortization of acquired intangible assets 764 3,896 3,057 11,175 Non-GAAP gross profit 30,842 25,174 23% 114,147 110,537 3% Non-GAAP gross margin 42% 39% 42% 44% GAAP operating 13,587 (56,700) * 52,129 (20,926) * income- continuing operations GAAP operating 18% (88%) * 19% (8%) * margin- continuing operations Adjustments: Share-based compensation 2,972 3,521 10,220 13,046 Amortization of acquired intangible assets 764 3,896 3,057 11,175 Impairment charge 60,497 60,497 Non-GAAP operating income 17,323 11,214 54% 65,406 63,792 3% Non-GAAP operating margin 23% 17% 24% 25%
'/>"/>
SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29

Related biology technology :

1. WuXi PharmaTech (NYSE: WX) Holds Its Third Life Science and Chemistry Awards Ceremony in Beijing
2. WuXi PharmaTech Selects Labcyte POD(TM) 810 Platform for High-Throughput Screening
3. WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year
4. Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline
5. WuXi PharmaTech Announces Second-Quarter 2009 Results
6. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
7. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
8. WuXi PharmaTech Receives Award from BASF
9. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
10. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
11. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... ON , Aug. 27, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: ... three and six-month periods ended June 30, 2015. Biorem,s complete second ... www.sedar.com ). FINANCIAL HIGHLIGHTS: in ,000,s except earnings per shareThree-months ... , 2014 , 2015 , 2014 ... 9,398 , 4,433 Gross profit , 1,656 ...
(Date:8/27/2015)... 27, 2015 In response to recent ... and The US Postal Service to no longer ... ,select agents, by the CDC, Marken reaffirmed today ... sensitive shipments. Marken uses its flexible ... and certified personnel to ensure the safe and ...
(Date:8/26/2015)... MO (PRWEB) , ... August 26, 2015 , ... ... it is increasing its investment in the development and manufacture of highly valued ... The company’s scientific team's extensive expertise with protein chemistry has led to ...
(Date:8/26/2015)... , Aug. 26, 2015 China Cord ... China,s leading provider of cord blood ... cell storage services, today announced that the Company has ... ("MO2"), an entity wholly owned by Mr. Yuen Kam, ... has acquired the outstanding shares (the "Shares") of  Excellent ...
Breaking Biology Technology:BIOREM Reports $718,000 Net Earnings for the Second Quarter 2BIOREM Reports $718,000 Net Earnings for the Second Quarter 3Marken Ensures Safe Transportation Of Select Agents And Toxins 2Lee Biosolutions Announces Increased Investment in the Development and Manufacturing of Biomarkers Used in Early Detection Of Heart Disease 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3
... WASHINGTON, June 11 Syngenta today ... to add an innovative antitoxin crop protection technology to the ... which is aimed at reducing aflatoxin, a toxin that can ... heat and drought stress. , , "The acquisition ...
... PharmaNet Development Group, Inc., a leading provider of clinical development services ... its participation at several international professional meetings during the month of June. ... 45th Drug Information Association (DIA) Annual Meeting, ... 321, ...
... Study to Evaluate FDA-Approved Topical Anesthetic Pretreatment , ... Inc. (Nasdaq: NGSX ) announced today that ... its proposed study to evaluate Qutenza(TM) in patients with ... anesthetic. As part of its ongoing new drug application ...
Cached Biology Technology:Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields 2Syngenta Acquires Innovative Bio-Control Technology to Improve Usable Crop Yields 3PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June 2NeurogesX Provides U.S. Regulatory Update for Qutenza(TM) 2NeurogesX Provides U.S. Regulatory Update for Qutenza(TM) 3NeurogesX Provides U.S. Regulatory Update for Qutenza(TM) 4
(Date:8/18/2015)... , Aug. 18, 2015  Navitas today ... contributor to the Submission Content Management webinar ... a non-profit forum. Dedicated to the Implementation of ... neutral platform for industry, vendors, health authorities, ... and work towards a standard method of ...
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions ... the entire spectrum of clinical research, is proud to ... the company,s comprehensive SaaS-based eClinical technology platform, has led ... the first two quarters of 2015.   Q2 2015 ... largest quarters measured by contract value sold in the ...
(Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
... This release is available in German . ... in many animal species. During mating season male testosterone ... and masculine features. Male bonobos, however, invest much more ... levels would collide with this increased tendency towards forming ...
... PROVIDENCE, R.I. [Brown University] For the 26 million ... way to check glucose levels. It is invasive and ... working on a new sensor that can check blood ... The technique takes advantage of a convergence of ...
... Spanish . There are some jobs ("dirty ... a certain amount of social rejection towards the people who ... to moral conflicts and ethical decisions related to performing those ... perspective, as in the case of a police officer who ...
Cached Biology News:Bonobos' unusual success story 2Biochip measures glucose in saliva, not blood 2Biochip measures glucose in saliva, not blood 3Moral imagination as a key to overcoming work-related stigmas 2
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... tissue microarrays are derived from Paraffin embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... coated slides. Sections are large (3-5 mm ...
... 2-D standards consist of seven reduced, denatured ... carbonic anhydrase, rabbit muscle GAPDH, bovine muscle ... with pIs ranging from 4.5 to 8.5 ... 76,000. These 2-D standards provide calibrated references ...
The PROTEAN II xi multi-cell 2-D conversion kit converts the PROTEAN II xi multi-cell to the PROTEAN II XL multi-cell for a wider format cell that accepts 17 to 18 cm IPG strips....
Biology Products: